{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.50","upperLimit":"100.00","value":"100.0"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"97.50","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"ORR was assessed for participants with NHL using response criteria per Lugano Classification.\n\nORR was defined as the percentage of participants who experienced either of the following based on investigator assessment:\n\n* partial metabolic response/ PR\n* complete metabolic response/ CR","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants in part 1a with NHL that received 80 mg AMG 397.","id":"OG000","title":"Part 1a: Participants With NHL - 80 mg AMG 397"},{"description":"All participants in part 1a with NHL that received 160 mg AMG 397.","id":"OG001","title":"Part 1a: Participants With NHL - 160 mg AMG 397"}],"paramType":"NUMBER","populationDescription":"Parts 2 and 3 were not initiated and did not enrol any participants, therefore results presented only included participants in part 1. Participants with NHL were only enrolled in part 1a, so therefore data is only presented for part 1a.\n\nFAS: All participants who were enrolled and received at least 1 dose of AMG 397.","reportingStatus":"POSTED","timeFrame":"Up to end of study (a maximum of 48 weeks)","title":"Overall Response Rate (ORR) for Participants With Non-Hodgkin's Lymphoma (NHL)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}